Lv3
300 积分 2025-05-10 加入
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
1天前
已完结
The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer
1天前
已完结
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
1天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1天前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1天前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
1天前
已完结
Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC)
1天前
待确认
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1天前
已完结
皖公网安备34019202002308
